PL3178817T3 - Postać amorficzna związku tetracyklicznego - Google Patents
Postać amorficzna związku tetracyklicznegoInfo
- Publication number
- PL3178817T3 PL3178817T3 PL15830197T PL15830197T PL3178817T3 PL 3178817 T3 PL3178817 T3 PL 3178817T3 PL 15830197 T PL15830197 T PL 15830197T PL 15830197 T PL15830197 T PL 15830197T PL 3178817 T3 PL3178817 T3 PL 3178817T3
- Authority
- PL
- Poland
- Prior art keywords
- amorphous form
- tetracyclic compound
- tetracyclic
- compound
- amorphous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014162899 | 2014-08-08 | ||
| PCT/JP2015/072450 WO2016021707A1 (ja) | 2014-08-08 | 2015-08-07 | ４環性化合物の非晶質体 |
| EP15830197.8A EP3178817B1 (en) | 2014-08-08 | 2015-08-07 | Amorphous form of tetracyclic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3178817T3 true PL3178817T3 (pl) | 2020-11-16 |
Family
ID=55263964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15830197T PL3178817T3 (pl) | 2014-08-08 | 2015-08-07 | Postać amorficzna związku tetracyklicznego |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10344014B2 (pl) |
| EP (2) | EP3660009A1 (pl) |
| JP (3) | JP6906308B2 (pl) |
| DK (1) | DK3178817T3 (pl) |
| ES (1) | ES2803577T3 (pl) |
| PL (1) | PL3178817T3 (pl) |
| TW (4) | TWI765410B (pl) |
| WO (1) | WO2016021707A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4588121B1 (ja) * | 2009-06-10 | 2010-11-24 | 中外製薬株式会社 | ４環性化合物 |
| AU2011291708B2 (en) | 2010-08-20 | 2015-03-19 | Chugai Seiyaku Kabushiki Kaisha | Composition containing tetracyclic compound |
| DK2902029T3 (en) | 2012-09-25 | 2018-10-29 | Chugai Pharmaceutical Co Ltd | RET INHIBITOR |
| EP3135287A4 (en) | 2014-04-25 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
| RU2720680C2 (ru) | 2014-06-18 | 2020-05-12 | Ф. Хоффманн-Ля Рош Аг | Новая фармацевтическая композиция, содержащая неионные сурфактанты |
| TWI765410B (zh) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體的用途 |
| CN106999432A (zh) | 2014-12-05 | 2017-08-01 | 阿拉贡药品公司 | 抗癌组合物 |
| RU2740261C2 (ru) | 2015-01-16 | 2021-01-12 | Чугаи Сейяку Кабусики Кайся | Комбинированное лекарственное средство |
| CN109219437A (zh) * | 2016-06-03 | 2019-01-15 | 阿拉贡药品公司 | 抗癌组合物 |
| CN110494422A (zh) | 2017-03-15 | 2019-11-22 | 太阳制药先进研究有限公司 | 4-甲基-3-喹啉-3-基乙炔基-苯甲酸n’-(2-氯-6-甲基-苯甲酰基)酰肼的新型无定形分散体 |
| EP3596049A4 (en) * | 2017-03-15 | 2021-01-13 | Sun Pharma Advanced Research Company Limited | NEW AMORPHIC DISPERSION OF CYCLOPROPANECARBOXYLIC ACID (5- {5- [N '- (2-CHLORO-6-METHYLBENZOYL) HYDRAZINOCARBONYL] -2-METHYL-PHENYLETHYNYL} -PYRIDIN-2-AMIDE |
| WO2019008520A1 (en) | 2017-07-05 | 2019-01-10 | Fresenius Kabi Oncology Limited | PROCESS FOR THE PREPARATION OF ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| EP3815688B1 (en) * | 2018-06-29 | 2023-12-06 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing poorly-soluble basic medicine |
| AR116113A1 (es) | 2018-09-04 | 2021-03-31 | Chugai Pharmaceutical Co Ltd | Método para fabricar un compuesto tetracíclico |
| EP3556754A1 (en) | 2018-12-07 | 2019-10-23 | Fresenius Kabi iPSUM S.r.l. | Process for the preparation of alectinib |
| EA202191370A1 (ru) * | 2018-12-14 | 2021-09-16 | Фуджифилм Корпорэйшн | Фармацевтическая композиция и способ ее получения |
| WO2021040027A1 (ja) * | 2019-08-30 | 2021-03-04 | 三栄源エフ・エフ・アイ株式会社 | 非晶質の難水溶性素材を含有する固体組成物、及びその製造方法 |
| CN114466641A (zh) * | 2019-08-30 | 2022-05-10 | 三荣源有限公司 | 含有非结晶的水溶性差的材料的固体组合物及其生产方法 |
| AR121187A1 (es) | 2019-12-27 | 2022-04-27 | Chugai Pharmaceutical Co Ltd | Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene |
| WO2022009235A1 (en) * | 2020-07-10 | 2022-01-13 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of gilteritinib fumarate |
| JP7419572B2 (ja) | 2021-01-29 | 2024-01-22 | 中外製薬株式会社 | 小児がん治療用医薬組成物 |
| WO2022176017A1 (ja) * | 2021-02-16 | 2022-08-25 | 大塚製薬株式会社 | 非晶質体及び当該非晶質体を含む組成物 |
| EP4119128A1 (en) * | 2021-07-13 | 2023-01-18 | Dr. Falk Pharma Gmbh | Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion |
| JPWO2023074785A1 (pl) | 2021-10-28 | 2023-05-04 | ||
| WO2023161233A1 (en) * | 2022-02-22 | 2023-08-31 | Synthon B.V. | Solid forms of alectinib and alectinib salts |
| WO2023179774A1 (en) * | 2022-03-25 | 2023-09-28 | Shenzhen Pharmacin Co., Ltd. | Amorphous solid dispersions and pharmaceutical compositions comprising the same |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699054A (en) * | 1953-10-09 | 1955-01-11 | Lloyd H Conover | Tetracycline |
| JPS4918630B1 (pl) | 1970-07-29 | 1974-05-11 | ||
| JPH0892090A (ja) | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| DE69505470T2 (de) | 1994-08-04 | 1999-05-12 | F. Hoffmann-La Roche Ag, Basel | Pyrrolocarbazol |
| CA2252701C (en) | 1996-05-01 | 2003-10-28 | Mississippi State University | Halo-substituted protein kinase c inhibitors |
| EP1178988B1 (en) | 1999-05-14 | 2007-02-28 | The Australian National University | Compounds and therapeutic methods |
| WO2002043704A1 (en) | 2000-12-01 | 2002-06-06 | Kyowa Hakko Kogyo Co., Ltd. | Composition improved in solubility or oral absorbability |
| JP2004067606A (ja) * | 2002-08-08 | 2004-03-04 | Zensei Yakuhin Kogyo Kk | イトラコナゾール経口投与製剤 |
| EP1603567A4 (en) | 2003-02-28 | 2006-10-18 | Inotek Pharmaceuticals Corp | TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF |
| DK1454992T3 (da) | 2003-03-07 | 2006-10-02 | Ist Naz Stud Cura Dei Tumori | Anaplastisk lymfomakinaseassay, reagenser og sammensætninger deraf |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
| AU2004295061B2 (en) | 2003-11-21 | 2008-11-20 | Novartis Ag | 1H-imidazoquinoline derivatives as protein kinase inhibitors |
| CA2548600A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| JP4927704B2 (ja) | 2004-03-19 | 2012-05-09 | シュペーデル・エクスペリメンタ・アーゲー | 有機化合物 |
| US7973061B2 (en) | 2004-03-31 | 2011-07-05 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| PL1786785T3 (pl) | 2004-08-26 | 2010-08-31 | Pfizer | Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe |
| AU2005288864B2 (en) * | 2004-09-30 | 2012-08-23 | Janssen Sciences Ireland Uc | HIV inhibiting 5-heterocyclyl pyrimidines |
| GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
| CN101304993A (zh) | 2005-11-07 | 2008-11-12 | Irm责任有限公司 | 作为ppar调节剂的化合物和组合物 |
| CA2647448A1 (en) * | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| EP1914240B1 (en) | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
| CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| EP2222647B1 (en) | 2006-10-23 | 2015-08-05 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| WO2008130951A1 (en) | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| PT2176231T (pt) | 2007-07-20 | 2016-12-09 | Nerviano Medical Sciences Srl | Derivados de indazol substituídos activos como inibidores de quinases |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| KR20120034639A (ko) | 2009-05-07 | 2012-04-12 | 아스트라제네카 아베 | 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750 |
| JP4588121B1 (ja) | 2009-06-10 | 2010-11-24 | 中外製薬株式会社 | ４環性化合物 |
| GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| AU2011291708B2 (en) * | 2010-08-20 | 2015-03-19 | Chugai Seiyaku Kabushiki Kaisha | Composition containing tetracyclic compound |
| JP5006987B2 (ja) | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | ４環性化合物を含む医薬 |
| CN102793929B (zh) * | 2012-09-07 | 2013-12-11 | 上海奥科达生物医药科技有限公司 | 一种制备稳定非晶态药物制剂的方法 |
| DK2902029T3 (en) | 2012-09-25 | 2018-10-29 | Chugai Pharmaceutical Co Ltd | RET INHIBITOR |
| JP2015185406A (ja) | 2014-03-25 | 2015-10-22 | トヨタ自動車株式会社 | 燃料電池システム及び燃料電池の水分量制御方法 |
| CN106458967A (zh) | 2014-04-25 | 2017-02-22 | 中外制药株式会社 | 四环化合物的新结晶 |
| EP3135287A4 (en) | 2014-04-25 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
| RU2720680C2 (ru) | 2014-06-18 | 2020-05-12 | Ф. Хоффманн-Ля Рош Аг | Новая фармацевтическая композиция, содержащая неионные сурфактанты |
| TWI765410B (zh) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體的用途 |
-
2015
- 2015-08-06 TW TW109139533A patent/TWI765410B/zh active
- 2015-08-06 TW TW104125739A patent/TWI718102B/zh active
- 2015-08-06 TW TW111132529A patent/TWI831347B/zh active
- 2015-08-06 TW TW111105131A patent/TWI803187B/zh active
- 2015-08-07 EP EP19218884.5A patent/EP3660009A1/en active Pending
- 2015-08-07 EP EP15830197.8A patent/EP3178817B1/en active Active
- 2015-08-07 ES ES15830197T patent/ES2803577T3/es active Active
- 2015-08-07 PL PL15830197T patent/PL3178817T3/pl unknown
- 2015-08-07 DK DK15830197.8T patent/DK3178817T3/da active
- 2015-08-07 US US15/501,267 patent/US10344014B2/en active Active
- 2015-08-07 WO PCT/JP2015/072450 patent/WO2016021707A1/ja active Application Filing
- 2015-08-07 JP JP2016540751A patent/JP6906308B2/ja active Active
-
2019
- 2019-05-29 US US16/425,603 patent/US10774067B2/en active Active
-
2020
- 2020-09-14 US US17/019,896 patent/US20210238160A1/en not_active Abandoned
-
2021
- 2021-05-10 JP JP2021079717A patent/JP7116825B2/ja active Active
-
2022
- 2022-07-29 JP JP2022121468A patent/JP7483804B2/ja active Active
- 2022-11-04 US US17/980,827 patent/US20230339885A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190284163A1 (en) | 2019-09-19 |
| JP2022153575A (ja) | 2022-10-12 |
| JP7116825B2 (ja) | 2022-08-10 |
| ES2803577T3 (es) | 2021-01-28 |
| JP6906308B2 (ja) | 2021-07-21 |
| EP3660009A1 (en) | 2020-06-03 |
| TW202222796A (zh) | 2022-06-16 |
| US20170217927A1 (en) | 2017-08-03 |
| US10344014B2 (en) | 2019-07-09 |
| TWI803187B (zh) | 2023-05-21 |
| EP3178817B1 (en) | 2020-06-10 |
| TW202322823A (zh) | 2023-06-16 |
| JP7483804B2 (ja) | 2024-05-15 |
| US20230339885A1 (en) | 2023-10-26 |
| TWI831347B (zh) | 2024-02-01 |
| TWI765410B (zh) | 2022-05-21 |
| DK3178817T3 (da) | 2020-07-13 |
| EP3178817A4 (en) | 2018-01-03 |
| JP2021119194A (ja) | 2021-08-12 |
| US20210238160A1 (en) | 2021-08-05 |
| EP3178817A1 (en) | 2017-06-14 |
| WO2016021707A1 (ja) | 2016-02-11 |
| TW201613906A (en) | 2016-04-16 |
| US10774067B2 (en) | 2020-09-15 |
| TWI718102B (zh) | 2021-02-11 |
| TW202115047A (zh) | 2021-04-16 |
| JPWO2016021707A1 (ja) | 2017-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3178817T3 (pl) | Postać amorficzna związku tetracyklicznego | |
| EP3136857A4 (en) | Crystalline form of baricitinib | |
| IL248991B (en) | Converted dihydroisoquinolinone compounds | |
| SI3380554T2 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
| EP3164128A4 (en) | Amorphous form of eliglustat hemitartarate | |
| ZA201701210B (en) | Substituted bicyclic compounds | |
| HK1244274A1 (zh) | C21h22ci2n4o2的晶型 | |
| PL3113773T3 (pl) | Krystaliczne postaci grapiprantu | |
| IL248627A0 (en) | Amorphous form of apramilst | |
| IL253479A0 (en) | Crystalline forms of efinconazole | |
| EP3207034A4 (en) | Anhydrous crystalline form of s-equol | |
| GB201419174D0 (en) | Crystalline forms | |
| GB201407694D0 (en) | Compound | |
| IL249907A0 (en) | Tricyclic substances containing a triazole ring | |
| IL249130A0 (en) | Preparation of piperidine-4-carbthioamide | |
| GB201407693D0 (en) | Compound | |
| PT3165222T (pt) | Utilização do composto de ftalida | |
| GB201416462D0 (en) | Compound for use | |
| GB201408759D0 (en) | Compound for use | |
| GB201400579D0 (en) | Compound |